

Executive summary for AntiVir-X:

Market Infectious Diseases in JP size: \$420M (CAGR: 6.8%).

Clinical trials found: 2.

Patent hits: 2.

Recommendation: Consider inhalation formulation feasibility studies and a Phase 2a trial for COPD.